Effect of Helicobacter Pylori Infection on the First-Line Treatment Outcomes in Patients With Immune Thrombocytopenic Purpura

dc.contributor.author Dogan, A.
dc.contributor.author Ekinci, O.
dc.contributor.author Ebinc, S.
dc.date.accessioned 2025-05-10T16:54:11Z
dc.date.available 2025-05-10T16:54:11Z
dc.date.issued 2022
dc.description.abstract OBJECTIVE: Helicobacter pylori (H. pylori) eradication therapy is known to increase the platelet count, but in immune thrombocytopenic purpura (ITP), the effect of H. pylori infection on the response to treatment is not clear. This study aims to determine whether the response to the first-line treatment is affected by the states of H. pylori-positivity and -negativity in ITP patients. PATIENTS AND METHODS: Adult newly diagnosed or chronic ITP patients who had not received eradication therapy for H. pylori infection were included. Characteristics of the patients, presence and severity of bleeding, initial platelet count, administered treatments, and treatment response rates were inspected. RESULTS: Of 119 total patients, 66 (55.5%) were female, 32 (26.9%) were H. pylori-positive, 87 (73.1%) were H. pylori-negative. H. pylori-positive and H. pylori- negative groups were not significantly different in terms of age (p=0.127), gender (p=0.078), diagnosis status (p=0.094) and the distribution of bleeding symptoms (p=0.712). The most common treatment was standard-dose steroid in both groups (62.5% vs. 68.9%, p=0.524). Rates of complete response, partial response, no response were comparable for the two groups (respectively, 75% vs. 73.6%, and 18.8% vs. 19.5%, and 6.2% vs. 6.9%), and there was no significant difference between the groups (p=0.283). CONCLUSIONS: It can be stated, according to the present study, that in ITP patients in whom treatment is indicated, the response to the firstline treatment without the administration of H. pylori eradication therapy is similar between H. pylori-positive and H. pylori-negative patients. © 2022 Verduci Editore s.r.l. All rights reserved. en_US
dc.identifier.doi 10.26355/eurrev_202206_28970
dc.identifier.issn 1128-3602
dc.identifier.scopus 2-s2.0-85132720859
dc.identifier.uri https://doi.org/10.26355/eurrev_202206_28970
dc.identifier.uri https://hdl.handle.net/20.500.14720/3022
dc.language.iso en en_US
dc.publisher Verduci Editore s.r.l en_US
dc.relation.ispartof European Review for Medical and Pharmacological Sciences en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject First-Line Treatment en_US
dc.subject Helicobacter Pylori en_US
dc.subject Immune Thrombocytopenic Purpura en_US
dc.title Effect of Helicobacter Pylori Infection on the First-Line Treatment Outcomes in Patients With Immune Thrombocytopenic Purpura en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.scopusid 24472686400
gdc.author.scopusid 57194114271
gdc.author.scopusid 55328081200
gdc.author.wosid Ebinç, Senar/Hnp-6891-2023
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.description.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
gdc.description.departmenttemp Dogan A., Department of Hematology, Faculty of Medicine, Yüzüncü Yil University, Van, Turkey; Ekinci O., Istinye University, Bahcesehir LIV Hospital, Hematology Unit, Istanbul, Turkey; Ebinc S., Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey en_US
gdc.description.endpage 4000 en_US
gdc.description.issue 11 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q2
gdc.description.startpage 3995 en_US
gdc.description.volume 26 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q2
gdc.identifier.pmid 35731071
gdc.identifier.pmid 35731071
gdc.identifier.wos WOS:000820248700027
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed

Files